<DOC>
	<DOCNO>NCT01288196</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , blood level , immune response CNTO 6785 administration healthy adult volunteer .</brief_summary>
	<brief_title>A Safety , Tolerability , Pharmacokinetics , Immunogenicity Study CNTO 6785 Healthy Volunteers</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither volunteer , physician , study staff know identity assign treatment ) , study evaluate safety , tolerability , pharmacokinetics ( blood level drug ) immunogenicity ( development antibody drug ) single dose CNTO 6785 administer healthy adult volunteer intravenously ( vein ) subcutaneous ( skin ) administration healthy adult volunteers.This first administration CNTO 6785 human ; therefore , clinical experience available . Healthy volunteer receive single dose 1 , 3 , 10 mg/kg CNTO 6785 placebo 30-minute intravenous ( IV ) ( injection blood vessel ) infusion single dose 3 mg/kg CNTO 6785 administer 3 subcutaneous ( skin ) ( SC ) injection .</detailed_description>
	<criteria>Healthy adult volunteer clinically significant abnormality determine investigator ( study physician ) Have body mass index ( BMI ) 1930 kg/m2 Be nonsmoker least 6 month prior study participation Women must postmenopausal surgically sterile Currently history clinically significant medical illness medical disorder ( include malignancy serious infection ) investigator ( study physician ) considers exclude volunteer study Major surgery significant trauma within 12 week screen Any volunteer plan undergo elective surgery within 4 week prior study agent administration end study Consumes , average , approximately 500 mg/day caffeine ( contain 5 cup tea coffee 8 can soda caffeinated product per day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>CNTO 6785</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>